Short answer
Neurogene Inc. (NGNE) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Updated positive Phase 1/2 NGN-401 data for females with Rett syndrome, potentially strengthening clinical and commercial prospects.
Neurogene Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated positive Phase 1/2 NGN-401 data for females with Rett syndrome, potentially strengthening clinical and commercial prospects
- Results discussed June 29, 2026 conference call and webcast
- Full efficacy and safety details contained in Exhibit 99.1, critical for assessing durability and development risk
Item 8.01 · Other Events
- Positive updated Phase 1/2 clinical data for NGN-401 Rett syndrome gene therapy
- Data cover females with Rett syndrome, supporting continued clinical development
- Presentation publicly released June 29, 2026, with detailed results in Exhibit 99.2
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurogene Inc. 8-K filings
Get the next NGNE 8-K as it lands
Follow NGNE for push alerts, or ask the research agent what this filing means.